VESTA: Veliparib vs. placebo bei NSCLC (SCC) (#564)
Laufzeit: 01.01.2014 - 31.12.2019
imported
Kurzfassung
A randomized, double blind, multicenter, phase 3 study comparing Veliparib plus Carboplatin and Paclitaxel versus placebo plus Carboplatin and Paclitaxel in previously untreated advanced or metastatic squamous Non Small Cell Lung Cancer (NSCLC)
